BioCentury | Aug 21, 2020
Finance

CF Foundation’s Longwood incubator fund to push early tech toward CF

The Cystic Fibrosis Foundation’s partnership with Longwood Fund aims to instill CF research as a priority in start-ups built around new technologies. If successful, the charity is hoping to partner with other VCs to broaden...
BioCentury | Aug 7, 2020
Finance

Aug. 6 Quick Takes: More pressure on China’s U.S. listings; busy Editas; Athenex bestows royalty on Sagard; Longwood, CFF launch incubator and more

Trump admin plan would pressure U.S.-listed Chinese companies A Trump administration working group plan has recommended that Chinese companies listed on a U.S. stock exchange provide the Public Company Accounting Oversight Board with access to...
BioCentury | Jun 30, 2020
Finance

Syncona’s Freeline mulls IPO after crossovers back gene therapy play

Rather than draw the second half of a planned $80 million round from founding investor Syncona, gene therapy developer Freeline has instead opted to raise $80 million from a syndicate that includes crossover firms, setting...
BioCentury | Apr 27, 2020
Deals

Vertex continues its march into neuromuscular diseases with Affinia deal

Vertex is diving deeper into genetic therapies for neuromuscular diseases through an $80 million deal with Affinia to develop new AAV vectors for the indications. Affinia Therapeutics will receive $80 million in up front and...
BioCentury | Dec 5, 2019
Finance

With $75M from Apple Tree, Limelight seeks to overcome limitations of genetic therapy

...via that method. “We’re building a multidisease, multiplatform company to tackle some big gaps in genetic therapy,”...
...non-viral delivery approach. “We’re building a multidisease, multiplatform company to tackle some big gaps in genetic therapy.”...
BioCentury | Jun 28, 2019
Product Development

How small companies can leverage big changes in rare diseases

Small companies bring to the table a range of advantages over large ones when it comes to rare diseases, according to Ovid CEO Jeremy Levin. But he’s learned the hard way that it doesn’t help...
BioCentury | Jun 7, 2019
Company News

Exonics takeout, expanded CRISPR deal vault Vertex into neuromuscular diseases

Via a pair of deals totaling $420 million in upfront payments late Thursday, Vertex expanded into neuromuscular diseases and bolstered its gene editing capabilities by acquiring Exonics, broadening its partnership with CRISPR Therapeutics and hiring...
BioCentury | Jan 19, 2018
Company News

ICER says Luxturna needs discounts to be cost-effective

In an evidence report published on Jan. 12, the Institute for Clinical and Economic Review said vision loss drug Luxturna voretigene neparvovec-rzyl from Spark Therapeutics Inc. (NASDAQ:ONCE) needs substantial discounts to be cost-effective. The institute...
BioCentury | Jan 12, 2018
Company News

ICER says Luxturna is not cost-effective

In an evidence report published Friday, the Institute for Clinical and Economic Review said vision loss drug Luxturna voretigene neparvovec-rzyl from Spark Therapeutics Inc. (NASDAQ:ONCE) needs substantial discounts to be cost-effective. The institute said while...
BioCentury | Jul 14, 2014
Emerging Company Profile

4D: AAV (r)evolution

...4D Molecular Therapeutics LLC San Francisco, Calif. Technology: AAV vectors optimized by directed evolution for genetic therapy...
Items per page:
1 - 10 of 139
BioCentury | Aug 21, 2020
Finance

CF Foundation’s Longwood incubator fund to push early tech toward CF

The Cystic Fibrosis Foundation’s partnership with Longwood Fund aims to instill CF research as a priority in start-ups built around new technologies. If successful, the charity is hoping to partner with other VCs to broaden...
BioCentury | Aug 7, 2020
Finance

Aug. 6 Quick Takes: More pressure on China’s U.S. listings; busy Editas; Athenex bestows royalty on Sagard; Longwood, CFF launch incubator and more

Trump admin plan would pressure U.S.-listed Chinese companies A Trump administration working group plan has recommended that Chinese companies listed on a U.S. stock exchange provide the Public Company Accounting Oversight Board with access to...
BioCentury | Jun 30, 2020
Finance

Syncona’s Freeline mulls IPO after crossovers back gene therapy play

Rather than draw the second half of a planned $80 million round from founding investor Syncona, gene therapy developer Freeline has instead opted to raise $80 million from a syndicate that includes crossover firms, setting...
BioCentury | Apr 27, 2020
Deals

Vertex continues its march into neuromuscular diseases with Affinia deal

Vertex is diving deeper into genetic therapies for neuromuscular diseases through an $80 million deal with Affinia to develop new AAV vectors for the indications. Affinia Therapeutics will receive $80 million in up front and...
BioCentury | Dec 5, 2019
Finance

With $75M from Apple Tree, Limelight seeks to overcome limitations of genetic therapy

...via that method. “We’re building a multidisease, multiplatform company to tackle some big gaps in genetic therapy,”...
...non-viral delivery approach. “We’re building a multidisease, multiplatform company to tackle some big gaps in genetic therapy.”...
BioCentury | Jun 28, 2019
Product Development

How small companies can leverage big changes in rare diseases

Small companies bring to the table a range of advantages over large ones when it comes to rare diseases, according to Ovid CEO Jeremy Levin. But he’s learned the hard way that it doesn’t help...
BioCentury | Jun 7, 2019
Company News

Exonics takeout, expanded CRISPR deal vault Vertex into neuromuscular diseases

Via a pair of deals totaling $420 million in upfront payments late Thursday, Vertex expanded into neuromuscular diseases and bolstered its gene editing capabilities by acquiring Exonics, broadening its partnership with CRISPR Therapeutics and hiring...
BioCentury | Jan 19, 2018
Company News

ICER says Luxturna needs discounts to be cost-effective

In an evidence report published on Jan. 12, the Institute for Clinical and Economic Review said vision loss drug Luxturna voretigene neparvovec-rzyl from Spark Therapeutics Inc. (NASDAQ:ONCE) needs substantial discounts to be cost-effective. The institute...
BioCentury | Jan 12, 2018
Company News

ICER says Luxturna is not cost-effective

In an evidence report published Friday, the Institute for Clinical and Economic Review said vision loss drug Luxturna voretigene neparvovec-rzyl from Spark Therapeutics Inc. (NASDAQ:ONCE) needs substantial discounts to be cost-effective. The institute said while...
BioCentury | Jul 14, 2014
Emerging Company Profile

4D: AAV (r)evolution

...4D Molecular Therapeutics LLC San Francisco, Calif. Technology: AAV vectors optimized by directed evolution for genetic therapy...
Items per page:
1 - 10 of 139